Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial

Cancer Epidemiology Biomarkers and Prevention

Volumn 23, Issue 5, 2014, Pages 847-856

  Gurel, Bora ^a   Lucia, M Scott ^f   Thompson Jr , Ian M ^g   Goodman, Phyllis J ⁱ   Tangen, Catherine M ⁱ   Kristal, Alan R ^j   Parnes, Howard L ^e   Hoque, Ashraful ^h   Lippman, Scott M ^k   Sutcliffe, Siobhan ^l   Peskoe, Sarah B ^c   Drake, Charles G ^a,b,d   Nelson, William G ^a,d   De Marzo, Angelo M ^a,d   Platz, Elizabeth A ^a,c,d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Department of Immunology ^*  (Colombia)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

^f UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^h UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

ⁱ SWOG STATISTICAL CENTER   (United States)

^j Fred Hutchinson Cancer Research Center   (United States)

^k UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^l USA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; CASE CONTROL STUDY; CHRONIC INFLAMMATION; CONTROLLED CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATITIS; BLOOD; CANCER GRADING; CANCER STAGING; CHRONIC DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; FOLLOW UP; INFLAMMATION; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PROGNOSIS; PROSTATE; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE;

CASE-CONTROL STUDIES; CHRONIC DISEASE; FOLLOW-UP STUDIES; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL RATE;

EID: 84899746407     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-13-1126     Document Type: Article

References (18)

1. Ames BN, Gold LS, Willett WC. The causes and prevention of cancer. Proc Natl Acad Sci U S A 1995;92: 5258-65.
2. Campisi J. Cancer and ageing: rival demons? Nat Rev Cancer 2003;3: 339-49.
3. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007;7: 256-69.
4. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63: 11-30.
5. Schatteman PH, Hoekx L, Wyndaele JJ, Jeuris W, Van Marck E. Inflammation in prostate biopsies of men without prostatic malignancy or clinical prostatitis: correlation with total serum PSA and PSA density. Eur Urol 2000;37: 404-12.
6. Gerstenbluth RE, Seftel AD, MacLennan GT, Rao RN, Corty EW, Ferguson K, et al. Distribution of chronic prostatitis in radical prostatectomy specimens with up-regulation of bcl-2 in areas of inflammation. J Urol 2002;167: 2267-70.
7. Di Silverio F, Gentile V, De Matteis A, Mariotti G, Giuseppe V, Antonio Luigi P, et al. Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. Eur Urol 2003;43: 164-75.
8. Nickel JC, Downey J, Young I, Boag S. Asymptomatic inflammation and/or infection in benign prostatic hyperplasia. BJU Int 1999;84: 976-81.
9. Thompson I, Goodman P, Tangen C, Lucia M, Miller G, Ford L, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349: 215-24.
10. Goodman PJ, Tangen CM, Kristal AR, Thompson IM, Lucia MS, Platz EA, et al. Transition of a clinical trial into translational research: the prostate cancer prevention trial experience. Cancer Prev Res 2010; 3: 1523-33.
11. Sutcliffe S, Alderete JF, Till C, Goodman PJ, Hsing AW, Zenilman JM, et al. Trichomonosis and subsequent risk of prostate cancer in the Prostate Cancer Prevention Trial. Int J Cancer 2009;124: 2082-7.
12. Nickel JC, True LD, Krieger JN, Berger RE, Boag AH, Young ID. Consensus development of a histopathological classification system for chronic prostatic inflammation. BJU Int 2001;87: 797-805.
13. Irani J, Goujon J, Ragni E, Peyrat L, Hubert J, Saint F, et al. High-grade inflammation in prostate cancer as a prognostic factor for biochemical recurrence after radical prostatectomy. Urology 1999;54: 467-72.
14. Davidsson S, Fiorentino M, Andren O, Fang F, Mucci LA, Varenhorst E, et al. Inflammation, focal atrophic lesions, and prostatic intraepithelial neoplasia with respect to risk of lethal prostate cancer. Cancer Epidemiol Biomarkers Prev 2011;20: 2280-7.
15. Yli-Hemminki TH, Laurila M, Auvinen A, Maattanen L, Huhtala H, Tammela TL, et al. Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostatespecific antigen (PSA) concentration in the Finnish prostate cancer screening trial. BJU Int 2013;112: 735-41.
16. Moreira DM, Nickel JC, Gerber L, Muller RL, Andriole GL, Castro- Santamaria R, et al. Baseline prostate inflammation is associated with a reduced risk of prostate cancer in men undergoing repeat prostate biopsy: Results from the REDUCE study. Cancer 2014;120: 190-6.
17. Yaman O, Gogus C, Tulunay O, Tokatli Z, Ozden E. Increased prostatespecific antigen in subclinical prostatitis: the role of aggressiveness and extension of inflammation. Urol Int 2003;71: 160-4.
18. Stancik I, Luftenegger W, Klimpfinger M, Muller MM, Hoeltl W. Effect of NIH-IV prostatitis on free and free-to-totalPSA. Eur Urol 2004;46: 760-4.